Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study
Therapeutic Advances in Neurological Disorders · 2026-08 · 19
DOI: 10.1177/17562864261472650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Neurological Disorders, online erschienen am 13.08.2026. Verfasst von Celia Oreja-Guevara und 30 weiteren Autor:innen. Beteiligte Einrichtung: CSUR Multiple Sclerosis, Department of Neurology, Hospital Universitario Clínico San Carlos, IdISCC, Madrid, Spain. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Farmacéutica S.A., Spain.
Abstract (Originalsprache)
Background
Siponimod is approved in Europe for active secondary progressive multiple sclerosis (SPMS), but real-world data on its treatment patterns and outcomes in people with SPMS (pwSPMS) is limited.
Objective
To assess the demographic and clinical characteristics, effectiveness, and safety of siponimod in pwSPMS in a real-world setting.
Design
Non-interventional/observational, retrospective, multicenter study (28 centers).
Methods
Patients (⩾18 years) with active SPMS treated with siponimod in routine care were included. Retrospective clinical, radiological, and laboratory data were collected for patients up to 24 months before and 12 months after siponimod treatment.
Results
In total, 210 participants were included (mean age: 52.5 ± 8.6 years; females: 71.0%). At treatment initiation, the mean Expanded Disability Status Scale (EDSS) score was 5.7 ± 1.2. The mean time since multiple sclerosis diagnosis and the median time since active SPMS diagnosis were 16.7 ± 8.9 years and 1.3 (0.3; 4.4) years, respectively. Common comorbidities included psychiatric disorders and dyslipidemia (20.6%, each). Regarding working status, 55.9% with available information showed incapacity for work. Prior to siponimod, 44.3% received highly effective therapies: fingolimod (20.5%), rituximab (9.5%), ocrelizumab (5.2%), natalizumab (4.8%), and alemtuzumab (2.4%). After 1 year, 82.8% of the patients remained stable in terms of disability progression, 94.3% were free of relapses, and 85.7% did not present radiological disease activity; 46.2% experienced adverse events, 8.6% experienced serious adverse events, and 26 (12.4%) patients discontinued permanently.
Conclusion
In the study cohort, pwSPMS had high disability scores and comorbidities; more than half were unable to work, and over 40% had previously received high-efficacy therapies. After 1 year of siponimod treatment, most pwSPMS showed no signs of disease activity, with stabilized EDSS scores and relapses and new T2 or gadolinium-T1 lesions, as well as a favorable safety profile.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CSUR Multiple Sclerosis, Department of Neurology, Hospital Universitario Clínico San Carlos, IdISCC, Madrid, Spain.
- Department of Medicine, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain.
- CSUR Multiple Sclerosis, Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
- Neurology Department, Hospital Universitario de Burgos, Burgos, Spain.
- CSUR Esclerosis Multiple, Neurology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
- Neurology Department, Hospital Universitario de Cáceres, Cáceres, Spain.
ORCID-Profile: Celia Oreja-Guevara, Jose Meca-Lallana, Ana María Alonso Torres
Förderung
- Novartis Farmacéutica S.A., Spain
Zitieren
APA
Oreja-Guevara, C., Gómez-Estévez, I., Agüado García, L., Martín Martínez, J., Gómez Gutiérrez, M., Gascón Giménez, F., Agüera Morales, E., Meca-Lallana, V., Barrero Hernández, F. J., González Quintanilla, V., Romero Pinel, L., Delgado Gil, V., Durán Ferreras, E., Blasco Quílez, R., Meca-Lallana, J., Landete Pascual, L., Aladro-Benito, Y., Boyero Durán, S., Gracia Gil, J., …, & Díaz Sánchez, M. (2026). Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. Therapeutic Advances in Neurological Disorders, 19. https://doi.org/10.1177/17562864261472650
Vancouver
Oreja-Guevara C, Gómez-Estévez I, Agüado García L, Martín Martínez J, Gómez Gutiérrez M, Gascón Giménez F, et al. Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study. Therapeutic Advances in Neurological Disorders. 2026;19. doi:10.1177/17562864261472650
BibTeX
@article{OrejaGuevara2026,
author = {Oreja-Guevara, Celia and Gómez-Estévez, Irene and Agüado García, Laura and Martín Martínez, Jesus and Gómez Gutiérrez, Montserrat and Gascón Giménez, Francisco and Agüera Morales, Eduardo and Meca-Lallana, Virginia and Barrero Hernández, Francisco Javier and González Quintanilla, Vicente and Romero Pinel, Lucía and Delgado Gil, Virginia and Durán Ferreras, Eduardo and Blasco Quílez, Rosario and Meca-Lallana, Jose and Landete Pascual, Lamberto and Aladro-Benito, Yolanda and Boyero Durán, Sabas and Gracia Gil, Julia and Caminero Rodríguez, Ana Belén and Cano Orgaz, Antonio Tomás and Eichau Madueño, Sara and Querol Pascual, María Rosa and Otano Martínez, María and Alonso Torres, Ana María and Calles Hernández, Carmen and López Real, Ana and Ares Luque, Adrián and Lorenzo González, Jose Ramón and Gómez Vicente, Lidia and Díaz Sánchez, María},
title = {Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study},
journal = {Therapeutic Advances in Neurological Disorders},
year = {2026},
volume = {19},
doi = {10.1177/17562864261472650}
}
EUVIMED